Dr. Clifford Henderson

Dr. Henderson grew up in Edmond, doing his undergraduate studies at Oklahoma Baptist University. After a few years as a Certified Financial Planner, Dr. Henderson returned to his original dream of becoming a physician. Dr. Henderson went to the University of Oklahoma College of Medicine where he was accepted into the prestigious academic honor society Alpha Omega Alpha for maintaining a 4.0 GPA through the first three years of medical school. Dr. Henderson did his dermatology training at OU Dermatology. He was fortunate to receive extensive training in Mohs surgery and reconstruction during his residency. Dr. Henderson is in the first ever class of doctors to become board certified in Mohs and Dermatologic Surgery, passing a rigorous exam and demonstrating years of experience performing Mohs surgery. Dr. Henderson's passion is the prevention, early detection and treatment of skin cancer. He uses a multitude of treatment methods, including Mohs surgery when needed according to Appropriate Use Criteria. Dr Henderson has an interconnected team of reconstructive surgeons, medical oncologists and radiation oncologists to ensure that his patients have the highest level of care no matter how early or advanced their skin cancer is. As one of two Mohs surgeons for the largest dermatology group in the state, Dr Henderson is proud to have performed Mohs surgery on thousands of patients in Oklahoma, Texas and Kansas. He and his highly experienced staff are honored to have the opportunity to care for you or your family member.

Dr. Henderson is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Nummular Eczema, Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Dr. Henderson is board certified in American Board Of Dermatology , American Board Of Mohs And Dermatologic Surgery , Drug Enforcement Administration , Oklahoma Bureau Of Narcotics And Dangerous Drugs , and Oklahoma State Board Of Medical Licensure & Supervision. He is actively involved in clinical research, co-authoring 1 peer reviewed article.